Eloxx Pharmaceuticals, Inc. Common Stock vs. Repligen Corp
Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| ELOX | RGEN | |
|---|---|---|
| Market Cap | $64.47 million | $9.42 billion |
| Revenue (TTM) | — | $785.10 million |
| Net Income (TTM) | — | $41.54 million |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| ELOX | RGEN | |
|---|---|---|
| P/E Ratio | — | 228.53 |
| Price / Book | 1.39 | 4.46 |
| Price / Sales | — | 11.99 |
ELOX leads on 1 of 1 valuation factors.
Profitability
| ELOX | RGEN | |
|---|---|---|
| Net Margin | — | 5.29% |
| Return on Equity | — | 1.97% |
ELOX and RGEN split the profitability factors evenly.
Risk & Sentiment
| ELOX | RGEN | |
|---|---|---|
| Short Interest | 0.01% | 7.13% |
ELOX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ELOX overview, ELOX financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.